NEEDHAM, Mass. and KYIV, Ukraine (August 19, 2025) – Trialt, a global clinical research organization (CRO) specializing in biostatistics, statistical programming, data management, and medical writing, has been awarded a Gold Stevie® Award for Company of the Year in the pharmaceutical industry in the 22nd Annual International Business Awards®.
The International Business
Awards are among the world’s most prestigious honors for business performance
and innovation. Organizations across more than 60 nations submitted nominations
for this year’s program. Trialt earned the top honor based on consistently high
scores from independent judges across multiple categories for its operational
excellence and impact across the global life sciences sector. “This recognition is clear proof of the
dedication and expertise of our entire biometrics and medical writing teams,”
said Michael Vulikh, CEO of Trialt. “We are proud to support pharmaceutical and
biotech sponsors across the world with services, tools, and resourcing that
helps move clinical trials forward, and we will continue to work in bringing
fresh approaches to the work that motivates us.” Trialt’s award-winning performance
includes its role in scaling biometrics operations for global sponsors,
delivering under pressure in complex rescue studies, and helping bring
AI-powered innovation to regulatory and market access operations. Meeting the Moment in a Rapidly
Expanding Market According to the Clinical Research Organization Global Market Report 2025,
the CRO market is projected to grow at a compound annual growth rate (CAGR) of
10 percent. Due to this, the pharmaceutical and biotechnology industries are
seeing a growing demand for globalized clinical trials, a sharp increase in
therapeutic complexity, and the urgent need for specialized expertise. Vulikh added, “As clinical trial sponsors
take on more ambitious drug development programs, they are seeking partners who
can scale quickly, deliver with consistency, and fill gaps in specialized
areas. This is why Trialt’s FSP resourcing model has been in such high demand
recently.” Trialt’s Functional Service Provider
(FSP) model offers sponsors the ability to deploy embedded talent across
biostatistics, programming, data management, and medical writing with minimal
ramp-up and maximum continuity. Trialt leaders have trained and integrated an
extensive amount of statistical programmers through its delivery framework to
support large sponsors and CROs meet critical milestones and scale without
hiring. To learn more about Trialt’s services,
visit www.trialt.com. For details on the 2025 International
Business Awards, visit www.StevieAwards.com/IBA.
About Trialt Trialt is the trusted CRO partner for
biostatistics, statistical programming, data management, and medical writing.
With expert teams across eight countries and deep engineering roots, we deliver
tailored solutions designed to move trials forward and produce measurable
results. Named “Company of the Year – Pharmaceutical Industry” in the 2025 International
Business Awards, sponsors turn to Trialt to scale complex programs, recover
at-risk studies, and meet critical timelines with confidence. Learn more at
www.trialt.com.
Media Contact Don F. McLean, +1734-716-4182
